Study of ASP0739 Alone and With Pembrolizumab in Advanced Solid Tumors With NY-ESO-1 Expression Participants

A Phase 1/2 Open-label Study Investigating the Safety, Tolerability and Efficacy of ASP0739 as a Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors Known to Express NY-ESO-1

The purpose of this study is to evaluate the safety, and tolerability of ASP0739, when administered as a single agent and in combination with pembrolizumab.

This study will also evaluate the clinical response and other measures of anticancer activity of ASP0739 when administered as a single agent and in combination with pembrolizumab based on central and local assessment.

Study Overview

• Status: Completed
• Conditions: Ovarian Cancer; NSCLC; Solid Tumors; ESCC
• Intervention / Treatment: Drug: Pembrolizumab; Drug: ASP0739

Detailed Description

The study is comprised of 2 phases. Phase 1 (dose escalation) includes participants with solid tumors known to express New York esophageal squamous cell carcinoma 1 (NY-ESO-1). Phase 2 (ASP0739 as single agent and in combination with pembrolizumab) includes participants with relapsed/refractory Synovial Sarcoma (SS), myxoid/round cell liposarcoma (MRCL), and ovarian cancer who have not responded to Standard of Care (SOC) or are ineligible for standard therapy. Phase 2 single agent will also include a cohort of participants with select solid tumors known to express NY-ESO-1 (melanoma, Non Small Cell Lung Cancer-adenocarcinoma [NSCLC], squamous cell and esophageal squamous cell carcinoma [ESCC]). Japanese participants will only be enrolled into the monotherapy arm of the dose expansion cohort.

• Study Type: Interventional
• Enrollment (Actual): 16
• Phase: Phase 2; Phase 1

Contacts and Locations

Study Locations

• United States
  • California
    • Duarte, California, United States, 91010
      • City of Hope
  • Florida
    • Miami, Florida, United States, 33136
      • University of Miami
  • Illinois
    • Chicago, Illinois, United States, 60611
      • Northwestern University Robert H. Lurie Comprehensive Cancer Center
    • Chicago, Illinois, United States, 60637
      • The University of Chicago Medicine
  • New York
    • New York, New York, United States, 10016
      • NYU Perlmutter Cancer Center
  • Rhode Island
    • Providence, Rhode Island, United States, 02903
      • Brown University

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

Phase 1 Dose Escalation only:

- Participant has relapsed/refractory (R/R) solid tumor known to express NY-ESO-1 after completing available Standard of Care (SOC) therapy or is not a candidate for SOC therapy. NY-ESO-1 expression status is not required for participant entry.

Safety Lead-in, Phase 2 Single agent and Combination Therapy only:

• Participant has relapsed/refractory (R/R) synovial sarcoma (SS) or myxoid/round cell liposarcoma (MRCL) disease after undergoing available SOC treatment or is not a candidate for SOC therapy (must have previously received either an anthracycline or ifosfamide containing regimen or another systemic regimen, if not a candidate for either agent).

  • Participant has not received prior checkpoint inhibitor therapy (i.e., Programmed Cell Death Protein 1 [PD-1]/Programmed Death Ligand 1 [PD-L1] treatment naive)
  • SS: confirmation by the presence of a translocation between SYT on the X chromosome and SSX1, SSX2, or SSX4 on chromosome 18 (may be presented in the pathology report as t [X;18]).
  • MRCL: confirmation by the presence of the reciprocal chromosomal translocation t (12;16) (q13;p11) or t(12;22)(q13;q12).

• Participant has R/R ovarian cancer that is:

  • platinum resistant OR platinum-sensitive, but the participant is not a candidate for platinum or other SOC therapy.
  • Participant has not received prior checkpoint inhibitor therapy (i.e., naive PD-1/PD-L1 treatment participants).
• Participant has R/R solid tumor (melanoma, non-small cell lung cancer [NSCLC]-adenocarcinoma and squamous cell, or esophageal squamous cell carcinoma [ESCC]) after available SOC treatment or is not a candidate for SOC therapy (single-agent only).
• Participant consents to provide an archival tumor specimen in a tissue block or unstained serial slides prior to IP administration.
• Participant in phase 2 consents to provide tumor specimen obtained within 56 days prior to first dose of study treatment, as tissue block or unstained serial slides.
• Participant in phase 2 consents to undergoing a tumor biopsy (core needle biopsy or excision) during the treatment period.
• Participant has an Eastern Cooperative Oncology Group (ECOG) performance status of <= 2.
• Participant with life expectancy of >= 12 weeks at the time of screening.
• Participant must meet criteria for clinical laboratory tests during screening period.

• A female participant is eligible to participate if she is not pregnant and at least one of the following conditions apply:

  • Not a woman of childbearing potential (WOCBP) OR
  • WOCBP who agrees to follow the contraceptive guidance throughout the treatment period and for at least 6 months after the final investigational product (IP) administration.
• Female participant must not be breastfeeding at screening or during the study period and for 6 months after the final IP administration.
• Female participant must not donate ova at screening and throughout the study period and for 6 months after the final IP administration.
• A male participant with female partner(s) of childbearing potential must agree to use contraception during the treatment period and for at least 6 months after the final IP administration.
• Male participant must not donate sperm starting at screening and throughout the study period and for 6 months after the final IP administration.
• Participant agrees not to participate in another interventional study while on treatment.
• Participant measurable disease according to RECIST 1.1. For participant with only 1 measurable lesion and prior radiotherapy, the lesion must be outside the field of prior radiotherapy or must have documented progression following radiation therapy.

Exclusion Criteria:

• Participant has persistent non-hematological toxicities of >= grade 2 (National Cancer Institute's Common Terminology Criteria for Adverse Events [NCI-CTCAE] version 5.0), with symptoms and objective findings from treatment (including chemotherapy, kinase inhibitors, immunotherapy, experimental agents, radiation or surgery).

• Participant has received any of the following therapies (for inclusion in the study, all abnormalities must have returned to <= grade 1):

  • Systemic immunomodulators (checkpoint inhibitors)-except the dose escalation phase and the NY-ESO-1 solid tumor (melanoma, NSCLC-adenocarcinoma and squamous cell and ESCC) cohorts in the dose expansion phase of monotherapy, which may have received prior checkpoint inhibitor therapy
  • Immunosuppressive drugs including steroids <= 14 days prior to treatment
  • Cytotoxic agents <= 14 days prior to treatment
  • Investigational agent <= 21 days prior to treatment or 5 half-lives, whichever is shorter
  • Radiation therapy <= 21 days prior to treatment
• Participant has clinically active or untreated nervous system metastases. Participants with previously treated Central Nervous System (CNS) metastases are eligible, if they are clinically stable and have no evidence of CNS progression by imaging for at least 4 weeks prior to start of study treatment and are not requiring immunosuppressive doses of systemic steroids (> 30 mg per day of hydrocortisone or > 10 mg per day of prednisone or equivalent) for longer than 2 weeks.
• Participant has an active autoimmune disease. Participant with type 1 diabetes mellitus, endocrinopathies stably maintained on appropriate replacement therapy, or skin disorders (e.g., vitiligo, psoriasis, or alopecia) not requiring systemic treatment are allowed.
• Participant was discontinued from prior immunomodulatory therapy due to a grade >= 3 toxicity that was mechanistically related (e.g., immune related) to the agent.
• Participant has known history of serious hypersensitivity reaction to a known ingredient of ASP0739 or pembrolizumab or severe hypersensitivity reaction to treatment with another monoclonal antibody.
• Participant has a prior malignancy active (i.e., requiring treatment or intervention) within the previous 2 years prior to screening visit, except for locally curable malignancies that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer or carcinoma in situ of the cervix or breast.
• Participant has received a prior allogeneic bone marrow or solid organ transplant.
• Participant has an active uncontrolled infection within 14 days of treatment.
• Participant is known to have human immunodeficiency virus infection.
• Participant has active hepatitis B or C or other active hepatic disorder or participant is on hepatitis treatment. Hepatitis C RNA testing is not required in participants with negative hepatitis C antibody testing.
• Participant has any condition which makes the participant unsuitable for study participation.
• Participant has had a major surgical procedure and has not completely recovered within 28 days prior to the start of study treatment.
• Participant has had a myocardial infarction or unstable angina within 6 months prior to the start of study treatment or currently has an uncontrolled illness including, but not limited to, symptomatic congestive heart failure, clinically significant cardiac disease, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
• Participant is expected to require another form of anti-cancer therapy while on study treatment.
• Participant has a known or suspected hypersensitivity to bovine-derived protein or has suspected hypersensitivity to any ingredients of ASP0739.

Additional Exclusion Criteria for Participants in Combination Therapy Cohorts

• Participants with a history of myocarditis or congestive heart failure (as defined by New York Heart Associated Functional Classification III or IV), as well as unstable angina, serious uncontrolled cardiac arrhythmia, uncontrolled infection, or myocardial infarction 6 months prior to study entry.
• Participants with active interstitial lung disease (ILD)/pneumonitis or a history of ILD/pneumonitis requiring treatment with systemic steroids.
• Participants with baseline pulse oximetry < 92% "on Room air."
• Participants must not have known microsatellite instability-high or deficient MisMatch Repair.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Sequential Assignment
• Masking: None (Open Label)

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Phase 1 ASP0739 Monotherapy Dose Escalation; Participants with R/R solid tumors known to express NY-ESO-1 will receive ASP0739 on day 1 of each 28-day cycle for up to 6 doses, to determine the Recommended Phase 2 Dose (RP2D).	Drug: ASP0739; Intravenous (IV)
Experimental: Phase 2 ASP0739 + Pembrolizumab Safety Lead-in; Participants with R/R SS, MRCL or ovarian cancer will receive RP2D of ASP0739 on day 1 of each 28-day cycle for up to 6 doses in combination with pembrolizumab on Cycle 1 Day 1, and then every 6 weeks up to 4 doses during the treatment period to determine the RP2D of ASP0739 with pembrolizumab. A total of 17 doses of pembrolizumab may be available for qualifying participants.	Drug: Pembrolizumab; Intravenous (IV); Drug: ASP0739; Intravenous (IV)
Experimental: Phase 2 ASP0739 Monotherapy Dose Expansion; Participants with R/R SS, MRCL, or ovarian cancer and other solid tumors known to express NY-ESO-1 (melanoma, NSCLC-adenocarcinoma, squamous cell, and ESCC) will receive RP2D of ASP0739 on day 1 of each 28-day cycle for up to 6 doses.	Drug: ASP0739; Intravenous (IV)
Experimental: Phase 2 ASP0739 + Pembrolizumab Dose Expansion; Participants with R/R SS, MRCL, or ovarian cancer will receive RP2D of ASP0739 with pembrolizumab on day 1 of each 28-day cycle for up to 6 doses, in combination with 4 doses of pembrolizumab administered on cycle 1 day 1, and then every 6 weeks during the treatment period. A total of 17 doses of pembrolizumab may be available for qualifying participants.	Drug: Pembrolizumab; Intravenous (IV); Drug: ASP0739; Intravenous (IV)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of participants with vital sign abnormalities and/or AEs	Number of participants with potentially clinically significant vital sign values.	Up to 27 months
Number of participants with laboratory value abnormalities and/or AEs	Number of participants with potentially clinically significant laboratory values.	Up to 27 months
Number of participants with 12-lead electrocardiogram (ECG) abnormalities and/or AEs	Number of participants with potentially clinically significant 12-lead ECG values.	Up to 27 months
Number of participants with physical exam abnormalities and/or AEs	Number of participants with potentially clinically significant physical exam values.	Up to 27 months
Number of participants at each grade of the Eastern Cooperative Oncology Group (ECOG) performance status	The ECOG scale will be used to assess performance status. Grades range from 0 (fully active) to 5 (dead). Negative change scores indicate an improvement. Positive scores indicate a decline in performance.	Up to 27 months
Incidence of Dose Limiting Toxicities (DLTs) for ASP0739 Single Agent	A DLT is defined as any of the following occurring within 28 days of the first dose on cycle 1 day 1 (C1D1) considered related to IP. Grade (Gr) ≥ 2 autoimmune reaction; Gr 3 immune-related adverse events (irAEs) not resolving to Gr ≤ 1 in 3-5 days; Gr 4 irAEs; Gr ≥ 3 non-hematological AEs not resolving to Gr ≤ 2 within 72 hours of onset; Gr 4 neutropenia; Gr 3 febrile neutropenia; Gr 4 thrombocytopenia; Gr 3 anemia/thrombocytopenia with transfusion; Gr 4 anemia; aspartate aminotransferase (AST)/alanine aminotransferase (ALT) > 5 x upper limit of normal (ULN) (Gr ≥ 3) without liver metastases; AST/ALT > 8 x ULN with liver metastases; Confirmed Hy's Law; Gr ≥ 3 liver function test (LFT) abnormality; Gr 5 toxicity; > 2 week delay in cycle 2 due to treatment-related toxicity.	28 days
Incidence of Dose Limiting Toxicities (DLTs) for ASP0739 + Pembrolizumab Safety Lead-in	A DLT is defined as any of the following occurring within 28 days of the first dose on C1D1 considered related to IP. Gr ≥ 2 autoimmune reaction; Gr 3 irAEs not resolving to Gr ≤ 1 in 3-5 days; Gr 4 irAEs; Gr ≥ 3 non-hematological AEs not resolving to Gr ≤ 2 within 72 hours of onset; Gr 4 neutropenia; Gr 3 febrile neutropenia; Gr 4 thrombocytopenia; Gr 3 anemia/thrombocytopenia with transfusion; Gr 3 thrombocytopenia with hospitalization; Gr 4 anemia; AST/ALT > 5 x ULN (Gr ≥ 3) without liver metastases; AST/ALT > 8 x ULN with liver metastases; Confirmed Hy's Law; Total Bilirubin > 3 x ULN (Gr ≥ 3); Gr ≥ 3 LFT abnormality; Gr 5 toxicity; > 2 week delay in cycle 2 due to treatment-related toxicity; Gr ≥ 2 pneumonitis; Gr ≥ 2 encephalopathy, meningitis, motor/sensory neuropathy; Guillain-Barre syndrome/myasthenic syndrome/myasthenia gravis; Infusion-related reaction requiring infusion discontinuation.	28 days
Number of Participants with adverse events (AEs)	An AE is any untoward medical occurrence in a participant temporally associated with the use of study IP, whether or not considered related to the study IP, and other study treatments. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study IP and other study treatments. This includes events related to the comparator and events related to the (study) procedures. AEs will be graded using NCI-CTCAE version 5.0.	Up to 27 months
Number of Participants with Serious Adverse Events (SAEs)	An AE is considered "serious" if the event results in death; is life threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; results in congenital anomaly/birth defect; other medically important events.	Up to 27 months
Objective Response Rate per Immune Response Evaluation Criteria in Solid Tumors (iRECIST) (iORR) by Independent Central Review	iORR is defined as the proportion of participants for each dose level whose best overall response is rated as confirmed Complete Response (iCR) or Partial Response (iPR) per iRECIST by Independent Central Review.	Up to 36 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Duration of Overall Survival (OS)	OS is defined as the time from the date of first dose until the date of death from any cause.	Up to 36 months
Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1	ORR is defined as the proportion of participants for each dose level whose best overall response is rated as Complete Response (CR) or Partial Response (PR) per RECIST v1.1.	Up to 36 months
Disease Control Rate per iRECIST (iDCR)	iDCR is defined as the proportion of participants for each dose level whose best overall response is rated as confirmed iCR, iPR or stable disease (SD), per iRECIST.	Up to 36 months
Disease Control Rate per RECIST v1.1 (DCR)	DCR is defined as the proportion of participants for each dose level whose best overall response is rated as confirmed CR, PR or stable disease (SD), per RECIST v1.1.	Up to 36 months
Progression-Free Survival per iRECIST (iPFS) by Independent Central Review	iPFS is defined as the time from the start of the study treatment until death from any cause or radiographic disease progression assessed per iRECIST, whichever comes first, as assessed by Independent Central Review.	Up to 36 months
iPFS per iRECIST by local assessment	iPFS is defined as the time from the start of the study treatment until death from any cause or radiographic disease progression assessed per iRECIST, whichever comes first, as assessed by local assessment.	Up to 36 months
Progression-Free Survival per RECIST v1.1 (PFS) by Independent Central Review	PFS is defined as the time from the start of the study treatment until death from any cause or radiographic disease progression assessed per RECIST v1.1, whichever comes first, as assessed by independent central review.	Up to 36 months
PFS per RECIST v1.1 by local assessment	PFS is defined as the time from the start of the study treatment until death from any cause or radiographic disease progression assessed per RECIST v1.1, whichever comes first, as assessed by local assessment.	Up to 36 months
Duration of Response per iRECIST (iDOR) by Independent Central Review	iDOR will be calculated only for the subgroup of participants with confirmed response iCR/iPR per iRECIST, as assessed by Independent Central Review.	Up to 36 months
iDOR per iRECIST by local assessment	iDOR will be calculated only for the subgroup of participants with confirmed response iCR/iPR per iRECIST, as assessed by local assessment.	Up to 36 months
Duration of Response per RECIST (DOR) v1.1 by Independent Central Review	DOR will be calculated only for the subgroup of participants with confirmed response CR/PR per RECIST v1.1, as assessed by Independent Central Review.	Up to 36 months
DOR per RECIST v1.1 by local assessment	DOR will be calculated only for the subgroup of participants with confirmed response CR/PR per RECIST v1.1, as assessed by local assessment.	Up to 36 months
ORR per iRECIST (iORR) by local assessment	iORR is defined as the proportion of participants for each dose level whose best overall response is rated as confirmed iCR or iPR, by local assessment.	Up to 36 months

Collaborators and Investigators

• Sponsor: Astellas Pharma Global Development, Inc.
• Investigators: Study Director: Medical Director, Astellas Pharma Global Development, Inc.

Study record dates

Study Major Dates

• Study Start (Actual): January 11, 2022
• Primary Completion (Actual): June 1, 2023
• Study Completion (Actual): June 1, 2023

Study Registration Dates

• First Submitted: June 18, 2021
• First Submitted That Met QC Criteria: June 18, 2021
• First Posted (Actual): June 25, 2021

Study Record Updates

• Last Update Posted (Actual): November 8, 2023
• Last Update Submitted That Met QC Criteria: November 7, 2023
• Last Verified: November 1, 2023

More Information

Terms related to this study

• Keywords: NSCLC; Ovarian Cancer; Solid Tumor; ESCC; NY-ESO-1; ASP0739; MRCL; R/R SS
• Additional Relevant MeSH Terms: Neoplasms; Urogenital Neoplasms; Neoplasms by Site; Genital Neoplasms, Female; Endocrine System Diseases; Ovarian Diseases; Adnexal Diseases; Gonadal Disorders; Endocrine Gland Neoplasms; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Genital Diseases; Genital Diseases, Female; Ovarian Neoplasms; Molecular Mechanisms of Pharmacological Action; Antineoplastic Agents; Antineoplastic Agents, Immunological; Immune Checkpoint Inhibitors; Pembrolizumab
• Other Study ID Numbers: 0739-CL-0101

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: Access to anonymized individual participant level data will not be provided for this trial as it meets one or more of the exceptions described on www.clinicalstudydatarequest.com under "Sponsor Specific Details for Astellas."
• IPD Sharing Time Frame: Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.
• IPD Sharing Access Criteria: Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.
• IPD Sharing Supporting Information Type: STUDY_PROTOCOL; SAP; CSR

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No